Perifosine treatment in chronic lymphocytic leukemia: Results of a phase II clinical trial and in vitro studies

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1067-1075

  Friedman, Daphne R ^a   Lanasa, Mark C ^a   Davis, Patricia H ^a   Allgood, Sallie D ^a,b   Matta, Karen M ^a,b   Brander, Danielle M ^a   Chen, Youwei ^a,b   Davis, Evan D ^a,b   Volkheimer, Alicia D ^a,b   Moore, Joseph O ^a   Gockerman, Jon P ^a   Sportelli, Peter ^c   Weinberg, J Brice ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c AKEBIA THERAPEUTICS   (United States)

Author keywords

AKT; Chronic lymphocytic leukemia (CLL); Perifosine; Phase II clinical trial; Phospho flow cytometry

Indexed keywords

PERIFOSINE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; PHOSPHORYLCHOLINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; DYSGEUSIA; EVENT FREE SURVIVAL; EX VIVO STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPONATREMIA; IN VITRO STUDY; INFECTION; LYMPHOCYTE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFECTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84899741089     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.824080     Document Type: Article

References (28)

1. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756-1765.
2. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27: 3994-4001.
3. Wierda W, O ' Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-4078.
4. Longo P G, Laurenti L, Gobessi S, et a l. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111: 846-855.
5. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, anovel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-1103.
6. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010; 16: 1033-1041.
7. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053-4062.
8. Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase I/II trial. J Clin Oncol 2011; 29: 4243-4249.
9. Hassanein NM, Perkinson KR, Alcancia F, et al. A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia. Am J Clin Pathol 2010; 133: 708-717.
10. Hallek M, Cheson B D, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
11. Weinberg JB, Volkheimer AD, Chen Y, et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol 2007; 82: 1063-1070.
12. Levesque MC, Ghosh DK, Beasley BE, et al. CLL cell apoptosis induced by nitric oxide synthase inhibitors: Correlation with lipid solubility and NOS1 dissociation constant. Leuk Res 2008; 32: 1061-100.
13. Woo EW, Messmann R, Sausville EA, et al. Quantitative determination of perifosine, anovel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatographyelectrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 2001; 759: 247-257.
14. Mowery YM, Weinberg JB, Kennedy MN, et al. LMP-420: A novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells. Leukemia 2010; 24: 1580-1587.
15. Therneau T. A package for survival analysis in S. R package version 2.36-14 [Internet]. 2012. Available from: Http://CRAN.R-project.org/ package-survival
16. Ritz C, Streibig J C. B ioassay analysis using R. J Stat Software 2005; 12: 1-22.
17. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
18. Furman RR, Byrd JC, Brown JR, et al. CAL-101, An isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010; 116(Suppl. 1): Abstract 55.
19. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3 '-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612.
20. Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002; 38: 1615-1621.
21. Vlahos CJ, Matter WF, Hui KY, et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5248.
22. Van Ummersen L, Binger K, Volkman J, et a l. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004; 10: 7450-7456.
23. Bendell JC, Nemunaitis J, Vukelja SJ, et al. Randomized placebocontrolled phase II trial of perifosine plus capecitabine as secondor third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 2011; 29: 4394-4400.
24. van der Luit AH, Vink SR, Klarenbeek JB, et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 2007; 6: 2337-2345.
25. Gajate C, Mollinedo F. E delfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109: 711-719.
26. Fu L, Kim YA, Wang X, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 2009; 69: 8967-8976.
27. David E, Sinha R, Chen J, et al. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res 2008; 14: 5090-5098.
28. Perl AE, Kasner MT, Shank D, et al. Single-cell pharmacodynamic monitoring of s6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res 2012; 18: 1716-1725.